SCHEMBL9890725

SCHEMBL9890725

CNC(=O)Cc1ccc(C)cc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 1/20 0.50
PTGDR2 Q9Y5Y4 1/20 0.48
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PTGS1 P23219 1/20 0.43
LMNA P02545 5/20 0.43
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890763 0.88 HDAC7 (0.47) HDAC7PTGDR2MEN1KMT2APTGS1
SCHEMBL9890649 0.84 PTGS1 (0.59) HDAC7PTGDR2MEN1KMT2APTGS1
SCHEMBL9890731 0.84 LMNA (0.48) LMNAALDH1A1RAB9AMAPTSMN1; SMN2
SCHEMBL2393525 0.84 PTGDR2 (0.47) PTGDR2MEN1KMT2ALMNAALDH1A1
SCHEMBL2397419 0.82 KMT2A (0.51) HDAC7KMT2ALMNAALDH1A1L3MBTL1
SCHEMBL9890724 0.81 PTGDR2 (0.50) HDAC7PTGDR2MEN1KMT2APTGS1
SCHEMBL2394292 0.81 FFAR1 (0.47) MEN1KMT2ALMNAALDH1A1L3MBTL1
SCHEMBL9892662 0.80 PTGDR2 (0.50) PTGDR2MEN1KMT2ALMNAALDH1A1
SCHEMBL8279418 0.79 HDAC7 (0.45) HDAC7PTGDR2LMNAALDH1A1RAB9A
SCHEMBL19574255 0.77 POLB (0.43) MEN1KMT2AALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HDAC7 217/4885PTGDR2 1062/4885MEN1 1467/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HDAC7 217/4885PTGDR2 1062/4885MEN1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.